What is the equity of Opthea this year?
Opthea has equity of -75.81 M USD this year.
Opthea Equity 2025
Opthea Equity
-75.81 M USD
Ticker
OPT.AX
ISIN
AU000000OPT2
WKN
A2AB8J
In 2025, Opthea's equity was -75.81 M USD, a 1,195.19% increase from the -5.85 M USD equity in the previous year.
Opthea Aktienanalyse
What does Opthea do?
Opthea Ltd is a biopharmaceutical company specializing in the development of novel therapies for various eye diseases. The company was founded in 1985 in Melbourne, Australia as a spin-off from the Burnet Institute for Medical Research and Public Health. Since then, Opthea has become a leading company in ophthalmology and is researching innovative therapies that have the potential to improve the lives of millions of patients worldwide. Opthea's business model is to develop novel therapies for various eye diseases and market these therapies through partnerships with established pharmaceutical companies. The company focuses on developing therapies based on the inhibition of growth factors and other signaling pathways that promote the development of abnormal blood vessels and inflammation. This therapeutic principle offers a promising way to effectively treat various eye diseases. Opthea specializes in developing therapies for the treatment of wet age-related macular degeneration (AMD), which is the leading cause of severe visual impairment in older people. Opthea is developing a therapy aimed at inhibiting the excessive formation of blood vessels in the macula of the eye, which can impair vision. The drug called OPT-302 is used in combination therapies with existing treatments for wet AMD and has the potential to slow down the progression of the disease and improve vision. In addition to the therapy for wet AMD, Opthea is also researching therapy options for other eye diseases such as diabetic retinopathy, retinal vein occlusion, and corneal diseases. Opthea has filed numerous patents in this field and collaborates with various academic and clinical partners to advance the development of innovative therapies. Another important component of Opthea's business model is collaboration with established pharmaceutical companies. In 2020, Opthea entered into a licensing agreement with the pharmaceutical company Novartis, which includes exclusive distribution and marketing rights for the drug OPT-302 in Europe, Japan, and other countries outside of North America. This partnership allows Opthea to benefit from collaboration with an experienced and established partner while maximizing the potential of its innovative therapy. In summary, Opthea is a promising company in ophthalmology that specializes in the development of innovative therapies for various eye diseases. The company works closely with academic and clinical partners and leverages the advantages of partnerships with established pharmaceutical companies to maximize the potential of its therapies. With the therapy for wet AMD already in the pipeline, Opthea is expected to develop further therapy options in the future that will contribute to improving the lives of millions of patients worldwide. Opthea ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Opthea's Equity
Opthea's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Opthea's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Opthea's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Opthea's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Opthea’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Opthea stock
What was the equity of Opthea compared to the previous year?
The equity of Opthea has increased/decreased by 1,195.19% increased compared to the previous year.
What impact does a high equity have on investors of Opthea?
A high equity is advantageous for investors of Opthea as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Opthea?
A low equity can be a risk for investors of Opthea, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Opthea affect the company?
An increase in equity of Opthea can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Opthea affect the company?
A reduction in equity of Opthea can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Opthea?
Some factors that can affect the equity of Opthea include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Opthea so important for investors?
The equity of Opthea is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Opthea take to change the equity?
To change equity, Opthea can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Opthea pay?
Over the past 12 months, Opthea paid a dividend of 0.15 USD . This corresponds to a dividend yield of about 21.32 %. For the coming 12 months, Opthea is expected to pay a dividend of -0.02 USD.
What is the dividend yield of Opthea?
The current dividend yield of Opthea is 21.32 %.
When does Opthea pay dividends?
Opthea pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Opthea?
Opthea paid dividends every year for the past 4 years.
What is the dividend of Opthea?
For the upcoming 12 months, dividends amounting to -0.02 USD are expected. This corresponds to a dividend yield of -3.24 %.
In which sector is Opthea located?
Opthea is assigned to the 'Health' sector.
Wann musste ich die Aktien von Opthea kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Opthea from 2/24/2005 amounting to 0.15 USD, you needed to have the stock in your portfolio before the ex-date on 2/4/2005.
When did Opthea pay the last dividend?
The last dividend was paid out on 2/24/2005.
What was the dividend of Opthea in the year 2024?
In the year 2024, Opthea distributed 0 USD as dividends.
In which currency does Opthea pay out the dividend?
The dividends of Opthea are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Opthea
Our stock analysis for Opthea Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Opthea Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
